SALK Physicians Leveraged Advanced IORT Technology to Offer Safe and Effective Cancer Treatment During the COVID-19 Pandemic
IntraOp Medical Corporation announced today that University Hospital Salzburg (SALK) Austria has treated its 150th patient since installing IntraOp’s third generation Mobetron system in January 2021. With extended gantry movement, automatic docking and streamlined treatment planning, IORT is more efficient, more effective, and more precise.
The Paracelsus Medical University Hospital Salzburg has been a pioneering thought leader in IORT for more than 20 years. Currently, SALK treats 200-250 cancer patients every year as part of their comprehensive care program. “We are delighted we were able to utilize the Mobetron to deliver electron IORT during surgery to our cancer patients during the COVID-19 pandemic. This proved particularly useful for low-risk breast cancer patients where we administered single day radiotherapy rather than 3 weeks of postoperative radiation, minimizing exposure risk to our patients.”, stated Professor Felix Sedlmayer, head of radiation oncology. “We will soon be expanding our IORT program to incorporate CT imaging and 3D treatment planning while broadening to new indications like pancreatic cancer.”
“We are delighted to have SALK and Professor Sedlmayer’s team established as a global reference center.” said Derek T. DeScioli, Chief Executive Officer of IntraOp Medical Corporation. “Their institution is trailblazing new technologies and indications that will advance IORT far into the future.”